Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge

Viral Immunology

Volumn 18, Issue 2, 2005, Pages 365-372

  Galarza, Jose M ^a   Latham, Theresa ^b   Cupo, Albert ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Wyeth   (United States)

^c Aton Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS LIKE PARTICLE VACCINE; INTERLEUKIN 12; PROTEIN M1; PROTEIN M2; SIALIDASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; MOUSE; NONHUMAN; PROTEIN EXPRESSION; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; CELL LINE; CELLS, CULTURED; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNIZATION; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS; INFLUENZA VACCINES; INTERLEUKIN-12; MICE; ORTHOMYXOVIRIDAE INFECTIONS; SPODOPTERA; VIRAL MATRIX PROTEINS; VIRION;

INFLUENZA VIRUS;

EID: 23344441590     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2005.18.365     Document Type: Article

References (26)

1. Belshe, R.B. 2004. Current status of live attenuated influenza virus vaccine in the US. Virus Res. 103:177-185.
2. Beyer, W.E., A.M. Palache, J.C. de Jong, A.D. Osterhaus. 2002. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 20:1340-1353.
3. Bridges, C.B., S.A. Harper, K. Fukuda, et al. 2003. Prevention and control of influenza: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR 52:1-34.
4. Cho, Y., S. Basta, W. Chen, et al. 2003. Heat-aggregated noninfectious influenza virus induces a more balanced CD8(+)-T-lymphocyte immunodominance hierarchy than infectious virus. J. Virol. 77:4679-4684.
5. Feldmann, H., H.D. Klenk. 1996. Marburg and Ebola viruses. Adv. Virus Res. 47:1-52.
6. Gaglani, M.J., P.A. Piedra, G.B. Herschler, et al. 2004. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A (H1N1) and B epidemic in healthy children. Arch. Pediatr. Adolesc. Med. 158:65-73.
7. Garber, D.A., M.B. Feinberg. 2003. AIDS vaccine development the long and winding road. AIDS Rev. 5:131-139.
8. Horimoto, T., A. Takada, K. Iwatsuki-Horimoto, et al. 2003. Generation of influenza A viruses with chimeric (type A/B) hemagglutinins. J. Virol. 77:8031-8038.
9. Jones, T., F. Allard, S.L. Cyr, et al. 2003. A nasal proteosome influenza vaccine containing baculovirus-derived hemagglutinin induces protective mucosal and systemic immunity. Vaccine 21:3706-3712.
10. Kang, S.-M., Q. Yao, L. Guo, R.W. Compans. 2003. Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J. Virol. 77:9823-9830.
11. Katz, J.M. 2004. Preparing for the next influenza pandemic. ASM News 70:412-419.
12. Kuiken, T., R. Fouchier, G. Rimmelzwaan, A. Osterhaus. 2003. Emerging viral infections in a rapidly changing world. Curr. Opin. Biotechnol. 14:641-646.
13. Lanciotti, R.S., J.T. Roehrig, V. Deubel, et al. 1999. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 286:2333-2337.
14. Latham, T., J.M. Galarza. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75:6154-6165.
15. Mounts, A.W., H. Kwong, H. S. Izurieta, et al. 1999. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J. Infect. Dis. 180:505-508.
16. Muszkat, M., E. Greenbaum, A. Ben-Yehuda, et al. 2003. Local and systemic immune response in nursing-home elderly following intranasal or intramuscular immunization with inactivated influenza vaccine. Vaccine 21:1180-1186.
17. Nicholson, K.G., R.G. Webster, A.J. Hay. 1998. Textbook of Influenza. Blackwell Science, Oxford, UK.
18. Ninomiya, A., K. Ogasawara, K. Kajino, et al. 2002. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine 20:3123-3129.
19. Noad, R., P. Roy. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:438-444.
20. Rota, P.A., M.S. Oberste, S.S. Monroe, et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
21. Takada, A., S. Matsushita, A. Ninomiya, et al. 2003. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21:3212-3218.
22. Tumpey, T.M., M. Renshaw, J.D. Clements, J.M. Katz. 2001. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J. Virol. 75:5141-5150.
23. Vincent, S.G., P.R. Cunningham, N.L. Stephens, et al. 1997. Quantitative densitometry of proteins stained with coomassie blue using a Hewlett Packard Scanjet scanner and Scanplot software. Electrophoresis 18:67-71.
24. Warfield, K.L., C.M. Bosio, B.C. Welcher, et al. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. PNAS 100:15889-15894.
25. Webby, R.J., R.G. Webster. 2003. Are we ready for pandemic influenza? Science 302:1519-1522.
26. Wharton, S.A., W. Weis, J.J. Skehel, D.C. Wiley. 1989. Structure, function, and antigenicity of the hemagglutinin of influenza virus. In: R.M. Krug (ed.). The Influenza Viruses. Plenum Press, New York, pp. 153-169.